Companies rush to develop “utterly transformative” gene therapies – HealthLeaders Media
|
Companies rush to develop “utterly transformative” gene therapies
HealthLeaders Media The approval of gene therapy for leukemia, expected in the next few months, will open the door to a radically new class of cancer treatments.Companies and universities are racing to develop these new therapies, which re-engineer and turbocharge … |
|
3 Key Things Every CAR–T Investor Should Watch
Madison.com But the long-term risks of CAR-T are still unknown. Delivering genetic material via a virus vector — a method used to transform regular T-cells into CAR–T cells — could have unknown, long-lasting impacts. Patients in these trials haven’t been … |
Seeking Alpha |
3 Key Things Every CAR-T Investor Should Watch — The Motley Fool
Motley Fool The first CAR-T therapy recently won a unanimous thumbs up for approval. But that doesn’t mean CAR-T stocks are out of the woods just yet. Biotech Bonanza: The Next Leg Up | Seeking AlphaSeeking Alpha |